List of therapeutic monoclonal antibodies
This is a list of therapeutic, diagnostic and preventive monoclonal antibodies, antibodies that are clones of a single parent cell. When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies.
The abbreviations in the column Type are as follows:
- mab: whole monoclonal antibody
- Fab: fragment, antigen-binding (one arm)
- F(ab')2: fragment, antigen-binding, including hinge region (both arms)
- Fab': fragment, antigen-binding, including hinge region (one arm)
- Variable fragments:
- scFv: single-chain variable fragment
- di-scFv: dimeric single-chain variable fragment
- sdAb: single-domain antibody
- Bispecific monoclonal antibodies:
- 3funct: trifunctional antibody
- BiTE: bi-specific T-cell engager
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA approved therapeutic monoclonal antibodies in the Monoclonal antibody therapy page.
Name | Trade name | Type | Source | Target | Approved | Use |
---|---|---|---|---|---|---|
3F8 | mab | mouse | GD2 ganglioside | neuroblastoma | ||
8H9[1] | mab | mouse | B7-H3 | neuroblastoma, sarcoma, metastatic brain cancers | ||
Abagovomab[2] | mab | mouse | CA-125 (imitation) | ovarian cancer | ||
Abciximab | ReoPro | Fab | chimeric | CD41 (integrin alpha-IIb) | Y | platelet aggregation inhibitor |
Abituzumab[3] | mab | humanized | CD51 | cancer | ||
Abrezekimab[4] | Fab | humanized | interleukin 13 | ? | ||
Abrilumab | mab | human | integrin α4β7 | inflammatory bowel disease, ulcerative colitis, Crohn's disease | ||
Actoxumab | mab | human | Clostridium difficile | Clostridium difficile colitis | ||
Adalimumab | Humira | mab | human | TNF-α | Y | Rheumatoid arthritis, Crohn's disease, Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Hemolytic disease of the newborn |
Adecatumumab[5] | mab | human | EpCAM | prostate and breast cancer | ||
Atidortoxumab[6] | mab | human | Staphylococcus aureus alpha toxin | ? | ||
Aducanumab | mab | human | beta-amyloid | Alzheimer's disease | ||
Afasevikumab[7] | mab | human | IL17A and IL17F | multiple sclerosis | ||
Afelimomab | F(ab')2 | mouse | TNF-α | sepsis | ||
Afutuzumab[8] | mab | humanized | CD20 | lymphoma | ||
Alacizumab pegol[9] | F(ab')2 | humanized | VEGFR2 | cancer | ||
Alemtuzumab[10] | Lemtrada, Campath | mab | humanized | CD52 | Y | Multiple sclerosis |
Alirocumab | Praluent | mab | human | PCSK9 | Y | hypercholesterolemia |
Altumomab pentetate | Hybri-ceaker | mab | mouse | CEA | colorectal cancer (diagnosis) | |
Amatuximab | mab | chimeric | mesothelin | cancer | ||
Anatumomab mafenatox | Fab | mouse | TAG-72 | non-small cell lung carcinoma | ||
Andecaliximab | mab | chimeric | gelatinase B | gastric cancer or gastroesophageal junction adenocarcinoma | ||
Anetumab ravtansine[3] | mab | human | MSLN | cancer | ||
Anifrolumab | mab | human | interferon α/β receptor | systemic lupus erythematosus | ||
Anrukinzumab[9] (= IMA-638)[11] | mab | humanized | IL-13 | asthma | ||
Apolizumab[12] | mab | humanized | HLA-DR ? | hematological cancers | ||
Aprutumab ixadotin[13] | mab | human | FGFR2 | ? | ||
Arcitumomab | CEA-Scan | Fab' | mouse | CEA | gastrointestinal cancers (diagnosis) | |
Ascrinvacumab | mab | human | activin receptor-like kinase 1 | cancer | ||
Aselizumab[14] | mab | humanized | L-selectin (CD62L) | severely injured patients | ||
Atezolizumab[15] | Tecentriq | mab | humanized | PD-L1 | Y | cancer |
Atinumab[16] | mab | human | RTN4 | ? | ||
Atorolimumab | mab | human | Rhesus factor | hemolytic disease of the newborn | ||
Avelumab[7] | Bavencio | mab | human | PD-L1 | Y | cancer |
Azintuxizumab vedotin[17] | mab | chimeric/humanized | CD319 | cancer | ||
Bapineuzumab[18] | mab | humanized | beta amyloid | Alzheimer's disease | ||
Basiliximab | Simulect | mab | chimeric | CD25 (α chain of IL-2 receptor) | Y | prevention of organ transplant rejections |
Bavituximab[2] | mab | chimeric | phosphatidylserine | cancer, viral infections | ||
BCD-100 | ? | human | PD-1 | melanoma | ||
Bectumomab | LymphoScan | Fab' | mouse | CD22 | non-Hodgkin's lymphoma (detection) | |
Begelomab[19] | mab | mouse | DPP4 | ? | ||
Belantamab mafodotin[4] | mab | humanized | BCMA | cancer | ||
Belimumab | Benlysta | mab | human | BAFF | Y | non-Hodgkin lymphoma etc. |
Bemarituzumab[6] | mab | humanized | FGFR2 | gastric cancer or gastroesophageal junction adenocarcinoma | ||
Benralizumab | Fasenra | mab | humanized | CD125 | Y | asthma |
Berlimatoxumab[6] | mab | human | Staphylococcus aureus bi-component leukocidin | ? | ||
Bermekimab | Xilonix | mab | human | IL1A | colorectal cancer | |
Bersanlimab[4] | mab | human | ICAM-1 | ? | ||
Bertilimumab[14] | mab | human | CCL11 (eotaxin-1) | severe allergic disorders | ||
Besilesomab[20] | Scintimun | mab | mouse | CEA-related antigen | inflammatory lesions and metastases (detection) | |
Bevacizumab[10] | Avastin | mab | humanized | VEGF-A | Y | metastatic cancer, retinopathy of prematurity |
Bezlotoxumab | Zinplava | mab | human | Clostridium difficile | Y | Clostridium difficile colitis |
Biciromab | FibriScint | Fab' | mouse | fibrin II, beta chain | thromboembolism (diagnosis) | |
Bimagrumab[21] | mab | human | ACVR2B | myostatin inhibitor | ||
Bimekizumab[22] | mab | humanized | IL 17A and IL 17F | ankylosing spondylitis, psoriasis | ||
Birtamimab | mab | chimeric | serum amyloid A protein | amyloidosis | ||
Bivatuzumab mertansine | mab | humanized | CD44 v6 | squamous cell carcinoma | ||
Bleselumab[7] | mab | human | CD40 | organ transplant rejection | ||
Blinatumomab | Blincyto | BiTE | mouse | CD19 | Y | pre-B ALL (CD19+) |
Blontuvetmab[23] | Blontress | mab | veterinary | CD20 | ||
Blosozumab[24] | mab | humanized | SOST | osteoporosis | ||
Bococizumab | mab | humanized | neural apoptosis-regulated proteinase 1 | dyslipidemia | ||
Brazikumab[25] | mab | human | IL23 | Crohn's disease | ||
Brentuximab vedotin | Adcentris | mab | chimeric | CD30 (TNFRSF8) | Y | Hodgkin lymphoma |
Briakinumab | mab | human | IL-12, IL-23 | psoriasis, rheumatoid arthritis, inflammatory bowel diseases, multiple sclerosis | ||
Brodalumab | Siliz | mab | human | IL-17 | Y | Plaque psoriasis |
Brolucizumab[15] | scFv | humanized | VEGFA | wet age-related macular degeneration | ||
Brontictuzumab[19] | mab | humanized | Notch 1 | cancer | ||
Burosumab[25] | Crysvita | mab | human | FGF 23 | Y | X-linked hypophosphatemia |
Cabiralizumab[23] | mab | humanized | CSF1R | metastatic pancreatic cancer | ||
Camidanlumab tesirine[6] | mab | human | CD25 | B-cell Hodgkin’s lymphoma, non-Hodgkin lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia | ||
Camrelizumab[13] | mab | humanized | PD-1 | hepatocellular carcinoma | ||
Canakinumab[26] | Ilaris | mab | human | IL-1 | Y | Cryopyrin-associated periodic syndrome |
Cantuzumab mertansine | mab | humanized | mucin CanAg | colorectal cancer etc. | ||
Cantuzumab ravtansine[24] | mab | humanized | MUC1 | cancers | ||
Caplacizumab[27] | Cablivi | sdAb | humanized | VWF | Y | thrombotic thrombocytopenic purpura, thrombosis |
Capromab pendetide | Prostascint | mab | mouse | prostatic carcinoma cells | Y | prostate cancer (detection) |
Carlumab | mab | human | MCP-1 | oncology/immune indications | ||
Carotuximab[23] | mab | chimeric | endoglin | angiosarcoma | ||
Catumaxomab[18] | Removab | 3funct | rat/mouse hybrid | EpCAM, CD3 | Y | ovarian cancer, malignant ascites, gastric cancer |
cBR96-doxorubicin immunoconjugate | mab | humanized | Lewis-Y antigen | cancer | ||
Cedelizumab | mab | humanized | CD4 | prevention of organ transplant rejections, treatment of autoimmune diseases | ||
Cemiplimab | Libtayo | mab | human | PCDC1 | Y | cutaneous squamous cell carcinoma |
Cergutuzumab amunaleukin[7] | mab | humanized | IL2 | cancer | ||
Certolizumab pegol[5] | Cimzia | Fab' | humanized | TNF-α | Y | Crohn's disease, Rheumatoid arthritis, axial spondyloarthritis, psoriasis arthritis |
Cetrelimab[4] | mab | human | PD-1 | cancer | ||
Cetuximab | Erbitux | mab | chimeric | EGFR | Y | metastatic colorectal cancer and head and neck cancer |
Cibisatamab[4] | mab | humanized | CEACAM5 | cancer | ||
Cirmtuzumab | ? | humanized | ROR1 | chronic lymphocytic leukemia | ||
Citatuzumab bogatox[8] | Fab | humanized | EpCAM | ovarian cancer and other solid tumors | ||
Cixutumumab | mab | human | IGF-1 receptor (CD221) | Y | solid tumors | |
Clazakizumab[28] | mab | humanized | IL6 | rheumatoid arthritis | ||
Clenoliximab | mab | chimeric | CD4 | rheumatoid arthritis | ||
Clivatuzumab tetraxetan | hPAM4-Cide | mab | humanized | MUC1 | pancreatic cancer | |
Codrituzumab[3] | mab | humanized | glypican 3 | cancer | ||
Cofetuzumab pelidotin[6] | mab | humanized | PTK7 | cancer | ||
Coltuximab ravtansine[3] | mab | chimeric | CD19 | cancer | ||
Conatumumab[8] | mab | human | TRAIL-R2 | cancer | ||
Concizumab[21] | mab | humanized | TFPI | bleeding | ||
Cosfroviximab[17] | ZMapp | mab | chimeric | ebolavirus glycoprotein | Ebola virus | |
Crenezumab | mab | humanized | 1-40-β-amyloid | Alzheimer's disease | ||
Crizanlizumab[13] | mab | humanized | selectin P | sickle-cell disease | ||
Crotedumab[23] | mab | human | GCGR | diabetes | ||
CR6261 | mab | human | Influenza A hemagglutinin | infectious disease/influenza A | ||
Cusatuzumab[4] | mab | humanized | CD70 | cancer | ||
Dacetuzumab[9] | mab | humanized | CD40 | hematologic cancers | ||
Daclizumab | Zenapax | mab | humanized | CD25 (α chain of IL-2 receptor) | Y | prevention of organ transplant rejections, multiple sclerosis |
Dalotuzumab | mab | humanized | IGF-1 receptor (CD221) | cancer etc. | ||
Dapirolizumab pegol[22] | mab | humanized | CD154 (CD40L) | ? | ||
Daratumumab[29] | Darzalex | mab | human | CD38 | Y | Multiple myeloma |
Dectrekumab[15] | mab | human | IL-13 | ? | ||
Demcizumab | mab | humanized | DLL4 | cancer | ||
Denintuzumab mafodotin[19] | mab | humanized | CD19 | cancer | ||
Denosumab[30] | Prolia | mab | human | RANKL | Y | osteoporosis, bone metastases etc. |
Depatuxizumab mafodotin[25] | mab | chimeric/humanized | EGFR | glioblastoma | ||
Derlotuximab biotin | mab | chimeric | histone complex | recurrent glioblastoma multiforme | ||
Detumomab | mab | mouse | B-lymphoma cell | lymphoma | ||
Dezamizumab[13] | mab | humanized | serum amyloid P component | ? | ||
Dinutuximab | Unituxin | mab | chimeric | GD2 ganglioside | Y | neuroblastoma |
Diridavumab | mab | human | hemagglutinin | influenza A | ||
Domagrozumab[23] | mab | humanized | GDF-8 | Duchenne muscular dystrophy | ||
Dorlimomab aritox[31] | F(ab')2 | mouse | ? | ? | ||
Dostarlimab[32] | mab | humanized | PCDP1 | cancer | ||
Drozitumab | mab | human | DR5 | cancer etc. | ||
DS-8201 | ? | humanized | HER2 | gastric or gastroesophageal junction adenocarcinoma | ||
Duligotuzumab[33] | mab | humanized | ERBB3 (HER3) | testicular cancer | ||
Dupilumab | Dupixent | mab | human | IL4 | Y | atopic diseases |
Durvalumab | Imfinzi | mab | human | PD-L1 | Y | cancer |
Dusigitumab | mab | human | ILGF2 | B-cell malignancies | ||
Duvortuxizumab[17] | scFv | chimeric/humanized | CD19, CD3E | cancer | ||
Ecromeximab[12] | mab | chimeric | GD3 ganglioside | malignant melanoma | ||
Eculizumab[12] | Soliris | mab | humanized | C5 | Y | paroxysmal nocturnal hemoglobinuria, atypical HUS |
Edobacomab | mab | mouse | endotoxin | sepsis caused by Gram-negative bacteria | ||
Edrecolomab | Panorex | mab | mouse | EpCAM | colorectal carcinoma | |
Efalizumab[34] | Raptiva | mab | humanized | LFA-1 (CD11a) | psoriasis (blocks T-cell migration) | |
Efungumab[2] | Mycograb | scFv | human | Hsp90 | invasive Candida infection | |
Eldelumab | mab | human | interferon gamma-induced protein | Crohn's disease, ulcerative colitis | ||
Elezanumab[13] | mab | human | RGMA | spinal cord injury and multiple sclerosis | ||
Elgemtumab[15] | mab | human | ERBB3 (HER3) | cancer | ||
Elotuzumab | Empliciti | mab | humanized | SLAMF7 | Y | multiple myeloma |
Elsilimomab | mab | mouse | IL-6 | ? | ||
Emactuzumab[19] | mab | humanized | CSF1R | cancer | ||
Emapalumab | Gamifant | mab | human | interferon gamma | hemophagocytic lymphohistiocytosis | |
Emibetuzumab | mab | humanized | HHGFR | cancer | ||
Emicizumab[7] | Hemlibra | mab | humanized | activated F9, F10 | Y | haemophilia A |
Enapotamab vedotin[4] | mab | human | AXL | cancer | ||
Enavatuzumab | mab | humanized | TWEAK receptor | cancer etc. | ||
Enfortumab vedotin | mab | human | nectin-4 | urothelial cancer | ||
Enlimomab pegol[35] | mab | mouse | ICAM-1 (CD54) | ? | ||
Enoblituzumab | mab | humanized | CD276 | cancer | ||
Enokizumab | mab | humanized | IL9 | asthma | ||
Enoticumab[33] | mab | human | DLL4 | ? | ||
Ensituximab | mab | chimeric | 5AC | cancer | ||
Epitumomab cituxetan[36] | mab | mouse | episialin | ? | ||
Epratuzumab | mab | humanized | CD22 | cancer, SLE | ||
Eptinezumab | mab | humanized | calcitonin gene-related peptide | migraine | ||
Erenumab[25] | Aimovig | mab | human | CGRP | Y | migraine |
Erlizumab[37] | F(ab')2 | humanized | ITGB2 (CD18) | heart attack, stroke, traumatic shock | ||
Ertumaxomab[18] | Rexomun | 3funct | rat/mouse hybrid | HER2/neu, CD3 | Y | breast cancer etc. |
Etaracizumab | Abegrin | mab | humanized | integrin αvβ3 | Y | melanoma, prostate cancer, ovarian cancer etc. |
Etigilimab[4] | mab | humanized | TIGIT | ? | ||
Etrolizumab | mab | humanized | integrin β7 | inflammatory bowel disease | ||
Evinacumab | mab | human | angiopoietin 3 | dyslipidemia | ||
Evolocumab[21] | Repatha | mab | human | PCSK9 | Y | hypercholesterolemia |
Exbivirumab[38] | mab | human | hepatitis B surface antigen | hepatitis B | ||
Fanolesomab[39] | NeutroSpec | mab | mouse | CD15 | appendicitis (diagnosis) | |
Faralimomab | mab | mouse | interferon receptor | ? | ||
Faricimab[4] | mab | humanized | VEGF-A and Ang-2 | angiogenesis, ocular vascular diseases | ||
Farletuzumab | mab | humanized | folate receptor 1 | ovarian cancer | ||
Fasinumab | mab | human | HNGF | acute sciatic pain | ||
FBTA05[40][41] | Lymphomun | 3funct | rat/mouse hybrid | CD20 | chronic lymphocytic leukaemia | |
Felvizumab | mab | humanized | respiratory syncytial virus | respiratory syncytial virus infection | ||
Fezakinumab[42][43] | mab | human | IL-22 | rheumatoid arthritis, psoriasis | ||
Fibatuzumab[7] | mab | humanized | ephrin receptor A3 | ? | ||
Ficlatuzumab | mab | humanized | HGF | cancer etc. | ||
Figitumumab | mab | human | IGF-1 receptor (CD221) | adrenocortical carcinoma, non-small cell lung carcinoma etc. | ||
Firivumab[19] | mab | human | influenza A virus hemagglutinin | ? | ||
Flanvotumab | mab | human | TYRP1 (glycoprotein 75) | melanoma | ||
Fletikumab | mab | human | IL 20 | rheumatoid arthritis | ||
Flotetuzumab[4] | di-scFv | humanized | IL 3 receptor | hematological malignancies | ||
Fontolizumab[12] | HuZAF | mab | humanized | IFN-γ | Crohn's disease etc. | |
Foralumab[44] | mab | human | CD3 epsilon | ? | ||
Foravirumab[8] | mab | human | rabies virus glycoprotein | rabies (prophylaxis) | ||
Fremanezumab[13] | Ajovy | mab | humanized | calcitonin gene-related peptide alpha | Y | migraine and cluster headache |
Fresolimumab | mab | human | TGF-β | idiopathic pulmonary fibrosis, focal segmental glomerulosclerosis, cancer | ||
Frovocimab[32] | mab | humanized | PCSK9 | hypercholesterolemia | ||
Frunevetmab[17] | mab | veterinary | NGF | ? | ||
Fulranumab | mab | human | NGF | pain | ||
Futuximab[33] | mab | chimeric | EGFR | cancer | ||
Galcanezumab[23] | Emgality | mab | humanized | calcitonin | Y | migraine |
Galiximab | mab | chimeric | CD80 | B-cell lymphoma | ||
Gancotamab | scFv | human | HER2/neu | cancer | ||
Ganitumab | mab | human | IGF-1 receptor (CD221) | cancer | ||
Gantenerumab[26] | mab | human | beta amyloid | Alzheimer's disease | ||
Gatipotuzumab[17] | mab | humanized | MUC1 | cancer | ||
Gavilimomab[37] | mab | mouse | CD147 (basigin) | graft versus host disease | ||
Gedivumab[17] | mab | human | hemagglutinin HA | ? | ||
Gemtuzumab ozogamicin | Mylotarg | mab | humanized | CD33 | Y | acute myelogenous leukemia |
Gevokizumab | mab | humanized | IL-1β | diabetes etc. | ||
Gilvetmab[17] | mab | veterinary | PCDC1 | ? | ||
Gimsilumab[6] | mab | human | CSF2 | rheumatoid arthritis | ||
Girentuximab[29] | Rencarex | mab | chimeric | carbonic anhydrase 9 (CA-IX) | Y | clear cell renal cell carcinoma[45] |
Glembatumumab vedotin[46][47] | mab | human | GPNMB | melanoma, breast cancer | ||
Golimumab[38] | Simponi | mab | human | TNF-α | Y | rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis |
Gomiliximab | mab | chimeric | CD23 (IgE receptor) | allergic asthma | ||
Gosuranemab | mab | humanized | tau protein | progressive supranuclear palsy | ||
Guselkumab | Tremfya | mab | human | IL23 | Y | psoriasis |
Ianalumab[6] | mab | human | BAFF-R | autoimmune hepatitis | ||
Ibalizumab[26] | Trogarzo | mab | humanized | CD4 | Y | HIV infection |
IBI308 | ? | human | PD-1 | squamous cell non-small cell lung cancer | ||
Ibritumomab tiuxetan | Zevalin | mab | mouse | CD20 | Y | non-Hodgkin's lymphoma |
Icrucumab | mab | human | VEGFR-1 | cancer etc. | ||
Idarucizumab[3] | Praxbind | mab | humanized | dabigatran | Y | reversal of anticoagulant effects of dabigatran |
Ifabotuzumab[13] | mab | humanized | EPHA3 | ? | ||
Igovomab | Indimacis-125 | F(ab')2 | mouse | CA-125 | ovarian cancer (diagnosis) | |
Iladatuzumab vedotin[6] | mab | humanized | CD97B | cancer | ||
IMAB362 | mab | human | CLDN18.2 | gastrointestinal adenocarcinomas and pancreatic tumor | ||
Imalumab[19] | mab | human | MIF | cancer | ||
Imaprelimab[4] | mab | humanized | MCAM | ? | ||
Imciromab | Myoscint | mab | mouse | cardiac myosin | Y | cardiac imaging |
Imgatuzumab[33] | mab | humanized | EGFR | cancer | ||
Inclacumab[27] | mab | human | selectin P | cardiovascular disease | ||
Indatuximab ravtansine[24] | mab | chimeric | SDC1 | cancer | ||
Indusatumab vedotin[15] | mab | human | GUCY2C | cancer | ||
Inebilizumab[7] | mab | humanized | CD19 | cancer, systemic sclerosis, multiple sclerosis | ||
Infliximab | Remicade | mab | chimeric | TNF-α | Y | rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease, ulcerative colitis |
Intetumumab[48][49] | mab | human | CD51 | solid tumors (prostate cancer, melanoma) | ||
Inolimomab | mab | mouse | CD25 (α chain of IL-2 receptor) | graft versus host disease | ||
Inotuzumab ozogamicin[20] | Besponsa | mab | humanized | CD22 | ALL | |
Ipilimumab[30] | Yervoy | mab | human | CD152 | Y | melanoma |
Iomab-B | ? | mouse | CD45 | ablation of bone marrow | ||
Iratumumab[30] | mab | human | CD30 (TNFRSF8) | Hodgkin's lymphoma | ||
Isatuximab | mab | chimeric | CD38 | multiple myeloma | ||
Iscalimab[4] | mab | human | CD40 | ? | ||
Istiratumab[6] | mab | human | IGF1R, CD221 | advanced solid tumors | ||
Itolizumab[44] | Alzumab | mab | humanized | CD6 | Y | psoriasis |
Ixekizumab | Taltz | mab | humanized | IL 17A | Y | autoimmune diseases |
Keliximab | mab | chimeric | CD4 | chronic asthma | ||
Labetuzumab[34] | CEA-Cide | mab | humanized | CEA | colorectal cancer | |
Lacnotuzumab[17] | mab | humanized | CSF1, MCSF | cancer | ||
Ladiratuzumab vedotin[6] | mab | humanized | LIV-1 | cancer | ||
Lampalizumab[33] | Fab | humanized | CFD | geographic atrophy secondary to age-related macular degeneration | ||
Lanadelumab[23] | Takhzyro | mab | human | kallikrein | Y | angioedema |
Landogrozumab[7] | mab | humanized | GDF-8 | muscle wasting disorders | ||
Laprituximab emtansine[23] | mab | chimeric | EGFR | ? | ||
Larcaviximab[17] | mab | chimeric | ebolavirus glycoprotein | Ebola virus | ||
Lebrikizumab | mab | humanized | IL-13 | asthma | ||
Lemalesomab[37] | mab | mouse | NCA-90 (granulocyte antigen) | diagnostic agent | ||
Lendalizumab[23] | mab | humanized | C5 | ? | ||
Lenvervimab[4] | mab | humanized | hepatitis B surfage antigen | hepatitis B | ||
Lenzilumab[19] | mab | human | CSF2 | chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia | ||
Lerdelimumab[10] | mab | human | TGF beta 2 | reduction of scarring after glaucoma surgery | ||
Leronlimab[4] | mab | humanized | CCR5 | ? | ||
Lesofavumab[17] | mab | human | hemagglutinin HA | ? | ||
Letolizumab[17] | scFv | humanized | TRAP | inflammatory diseases | ||
Lexatumumab[2] | mab | human | TRAIL-R2 | cancer | ||
Libivirumab[38] | mab | human | hepatitis B surface antigen | hepatitis B | ||
Lifastuzumab vedotin | mab | humanized | phosphate-sodium co-transporter | cancer | ||
Ligelizumab[33] | mab | humanized | IGHE | severe asthma and chronic spontaneous urticaria | ||
Loncastuximab tesirine[6] | mab | chimeric | CD19 | cancer | ||
Losatuxizumab vedotin[17] | mab | chimeric/humanized | EGRF, ERBB1 HER1 | cancer | ||
Lilotomab satetraxetan[15] | mab | mouse | CD37 | cancer | ||
Lintuzumab | mab | humanized | CD33 | cancer | ||
Lirilumab[33] | mab | human | KIR2D | solid and hematological cancers | ||
Lodelcizumab[21] | mab | humanized | PCSK9 | hypercholesterolemia | ||
Lokivetmab[15] | Cytopoint[50] | mab | veterinary | Canis lupus familiaris IL31 | Y | clinical signs of atopic dermatitis in dogs[50] |
Lorvotuzumab mertansine | mab | humanized | CD56 | cancer | ||
Lucatumumab[9] | mab | human | CD40 | multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's lymphoma | ||
Lulizumab pegol | mab | humanized | CD28 | autoimmune diseases | ||
Lumiliximab[5] | mab | chimeric | CD23 (IgE receptor) | chronic lymphocytic leukemia | ||
Lumretuzumab[19] | mab | humanized | ERBB3 (HER3) | cancer | ||
Lupartumab amadotin[13] | mab | human | LYPD3 | ? | ||
Lutikizumab[13] | mab | humanized | interleukin 1 alpha | ? | ||
Mapatumumab[18] | mab | human | TRAIL-R1 | cancer | ||
Margetuximab | mab | humanized | HER2 | breast cancer | ||
Marstacimab | mab | human | TFPI | bleeding with hemophilia | ||
Maslimomab | ? | mouse | T-cell receptor | |||
Mavrilimumab | mab | human | GMCSF receptor α-chain | rheumatoid arthritis | ||
Matuzumab[14] | mab | humanized | EGFR | colorectal, lung and stomach cancer | ||
Mepolizumab | Bosatria | mab | humanized | IL-5 | Y | asthma and white blood cell diseases |
Metelimumab[39] | mab | human | TGF beta 1 | systemic scleroderma | ||
Milatuzumab[9] | mab | humanized | CD74 | multiple myeloma and other hematological malignancies | ||
Minretumomab | mab | mouse | TAG-72 | tumor detection (and therapy?) | ||
Mirikizumab[6] | mab | humanized | IL23A | psoriasis | ||
Mirvetuximab soravtansine | mab | chimeric | folate receptor alpha | ovarian cancer | ||
Mitumomab | mab | mouse | GD3 ganglioside | small cell lung carcinoma | ||
Modotuximab | mab | chimeric | EGFR extracellular domain III | cancer | ||
Mogamulizumab | Poteligeo | mab | humanized | CCR4 | Y | adult T-cell leukemia/lymphoma |
Monalizumab[7] | mab | humanized | NKG2A | rheumatoid arthritis, gynecologic malignancies, and other cancers | ||
Morolimumab | mab | human | Rhesus factor | |||
Mosunetuzumab[6] | mab | humanized | CD3E, MS4A1, CD20 | cancer | ||
Motavizumab[2] | Numax | mab | humanized | respiratory syncytial virus | respiratory syncytial virus (prevention) | |
Moxetumomab pasudotox | Lumoxiti | mab | mouse | CD22 | Y | hairy cell leukemia |
Muromonab-CD3 | Orthoclone OKT3 | mab | mouse | CD3 | prevention of organ transplant rejections | |
Nacolomab tafenatox | Fab | mouse | C242 antigen | colorectal cancer | ||
Namilumab[16] | mab | human | CSF2 | |||
Naptumomab estafenatox[51] | Fab | mouse | 5T4 | non-small cell lung carcinoma, renal cell carcinoma | ||
Naratuximab emtansine[23] | mab | chimeric | CD37 | |||
Narnatumab | mab | human | RON | cancer | ||
Natalizumab | Tysabri | mab | humanized | integrin α4 | Y | multiple sclerosis, Crohn's disease |
Navicixizumab[23] | mab | chimeric/humanized | DLL4 | cancer | ||
Navivumab[7] | mab | human | influenza A virus hemagglutinin HA | |||
Naxitamab | ? | humanized | c-Met | high-risk neuroblastoma and refractory osteomedullary disease | ||
Nebacumab | mab | human | endotoxin | sepsis | ||
Necitumumab[52] | Portrazza | mab | human | EGFR | Y | non-small cell lung carcinoma |
Nemolizumab[15] | mab | humanized | IL31RA | eczema[53] | ||
NEOD001 | ? | humanized | amyloid | primary systemic amyloidosis | ||
Nerelimomab | mab | mouse | TNF-α | ? | ||
Nesvacumab | mab | human | angiopoietin 2 | cancer | ||
Netakimab[4] | mab | chimeric | interleukin 17A | ? | ||
Nimotuzumab[30][54] | Theracim, Theraloc | mab | humanized | EGFR | Y | squamous cell carcinoma, head and neck cancer, nasopharyngeal cancer, glioma |
Nirsevimab | mab | human | RSVFR | respiratory syncytial virus | ||
Nivolumab | Opdivo | mab | human | PD-1 | Y | cancer |
Nofetumomab merpentan | Verluma | Fab | mouse | ? | cancer (diagnosis) | |
Obiltoxaximab | Anthim | mab | chimeric | Bacillus anthracis anthrax | Y | Bacillus anthracis spores |
Obinutuzumab | Gazyva | mab | humanized | CD20 | Y | Chronic lymphatic leukemia |
Ocaratuzumab | mab | humanized | CD20 | cancer | ||
Ocrelizumab[30] | Ocrevus | mab | humanized | CD20 | Y | rheumatoid arthritis, lupus erythematosus etc. |
Odulimomab | mab | mouse | LFA-1 (CD11a) | prevention of organ transplant rejections, immunological diseases | ||
Ofatumumab[18] | Arzerra | mab | human | CD20 | Y | chronic lymphocytic leukemia etc. |
Olaratumab | Lartruvo | mab | human | PDGF-R α | Y | cancer |
Oleclumab[17] | mab | human | 5'-nucleotidase | pancreatic and colorectal cancer | ||
Olendalizumab | mab | humanized | complement C5a | systemic lupus erythematosus, lupus nephritis, acute graft-versus-hose disease | ||
Olokizumab[44] | mab | humanized | IL6 | rheumatoid arthritis | ||
Omalizumab[37] | Xolair | mab | humanized | IgE Fc region | Y | allergic asthma |
Omburtamab[32] | mab | mouse | CD276 | cancer | ||
OMS721 | ? | human | MASP-2 | atypical hemolytic uremic syndrome | ||
Onartuzumab | mab | humanized | human scatter factor receptor kinase | cancer | ||
Ontuxizumab | mab | chimeric/humanized | TEM1 | cancer | ||
Onvatilimab[4] | mab | human | VSIR | ? | ||
Opicinumab | mab | human | LINGO-1 | multiple sclerosis | ||
Oportuzumab monatox[52] | Vicinium | scFv | humanized | EpCAM | bladder cancer | |
Oregovomab[39] | OvaRex | mab | mouse | CA-125 | ovarian cancer | |
Orticumab[33] | mab | human | oxLDL | |||
Otelixizumab[9] | mab | chimeric/humanized | CD3 | diabetes mellitus type 1 | ||
Otilimab | mab | human | GMCSF | osteoarthritis, rheumatoid arthritis | ||
Otlertuzumab | mab | humanized | CD37 | cancer | ||
Oxelumab | mab | human | OX-40 | asthma | ||
Ozanezumab | mab | humanized | NOGO-A | ALS and multiple sclerosis | ||
Ozoralizumab | mab | humanized | TNF-α | inflammation | ||
Pagibaximab[18] | mab | chimeric | lipoteichoic acid | sepsis (Staphylococcus) | ||
Palivizumab | Synagis, Abbosynagis | mab | humanized | F protein of respiratory syncytial virus | Y | respiratory syncytial virus (prevention) |
Pamrevlumab[7] | mab | human | CTGF | idiopathic pulmonary fibrosis (IPF), pancreatic cancer | ||
Panitumumab[38] | Vectibix | mab | human | EGFR | Y | colorectal cancer |
Pankomab | mab | humanized | tumor specific glycosylation of MUC1 | ovarian cancer | ||
Panobacumab[52] | mab | human | Pseudomonas aeruginosa | Pseudomonas aeruginosa infection | ||
Parsatuzumab[33] | mab | human | EGFL7 | cancer | ||
Pascolizumab[12] | mab | humanized | IL-4 | asthma | ||
Pasotuxizumab[19] | mab | chimeric/humanized | folate hydrolase | cancer | ||
Pateclizumab[24] | mab | humanized | LTA | TNF | ||
Patritumab[27] | mab | human | ERBB3 (HER3) | cancer | ||
PDR001 | ? | humanized | PD-1 | melanoma | ||
Pembrolizumab | Keytruda | mab | humanized | PD-1 | Y | melanoma and other cancers |
Pemtumomab | Theragyn | ? | mouse | MUC1 | cancer | |
Perakizumab[33] | mab | humanized | IL 17A | arthritis | ||
Pertuzumab | Omnitarg | mab | humanized | HER2/neu | Y | cancer |
Pexelizumab[34] | scFv | humanized | C5 | reduction of side effects of cardiac surgery | ||
Pidilizumab | mab | humanized | PD-1 | cancer and infectious diseases | ||
Pinatuzumab vedotin[21] | mab | humanized | CD22 | cancer | ||
Pintumomab | mab | mouse | adenocarcinoma antigen | adenocarcinoma (imaging) | ||
Placulumab | mab | human | human TNF | pain and inflammatory diseases | ||
Plozalizumab[7] | mab | humanized | CCR2 | diabetic nephropathy and arteriovenous graft patency | ||
Pogalizumab[23] | mab | humanized | TNFR superfamily member 4 | ? | ||
Polatuzumab vedotin[21] | mab | humanized | CD79B | diffuse large B-cell lymphoma | ||
Ponezumab | mab | humanized | human beta-amyloid | Alzheimer's disease | ||
Porgaviximab[17] | mab | chimeric | Zaire ebolavirus glycoprotein | Ebola virus disease | ||
Prasinezumab[6] | mab | humanized | NACP | Parkinson's disease | ||
Prezalizumab[23] | mab | humanized | ICOSL | ? | ||
Priliximab | mab | chimeric | CD4 | Crohn's disease, multiple sclerosis | ||
Pritoxaximab[21] | mab | chimeric | E. coli shiga toxin type-1 | ? | ||
Pritumumab | mab | human | vimentin | brain cancer | ||
PRO 140 | ? | humanized | CCR5 | HIV infection | ||
Quilizumab[27] | mab | humanized | IGHE | asthma | ||
Racotumomab[52] | Vaxira | mab | mouse | NGNA ganglioside | Y | non-small cell lung cancer |
Radretumab[16] | mab | human | fibronectin extra domain-B | cancer | ||
Rafivirumab[8] | mab | human | rabies virus glycoprotein | rabies (prophylaxis) | ||
Ralpancizumab | mab | humanized | neural apoptosis-regulated proteinase 1 | dyslipidemia | ||
Ramucirumab | Cyramza | mab | human | VEGFR2 | Y | solid tumors |
Ranevetmab | mab | veterinary | NGF | osteoarthritis in dogs | ||
Ranibizumab[5] | Lucentis | Fab | humanized | VEGF-A | Y | macular degeneration (wet form) |
Raxibacumab[20] | mab | human | anthrax toxin, protective antigen | Y | anthrax (prophylaxis and treatment) | |
Ravagalimab[4] | mab | humanized | CD40 | ? | ||
Ravulizumab[6] | mab | humanized | C5 | paroxysmal nocturnal hemaglobinuria, atypical hemolytic uremic syndrome | ||
Refanezumab | mab | humanized | myelin-associated glycoprotein | recovery of motor function after stroke | ||
Regavirumab | mab | human | cytomegalovirus glycoprotein B | cytomegalovirus infection | ||
Relatlimab | mab | human | LAG3 | melanoma | ||
Remtolumab[13] | mab | human | interleukin 17 alpha, TNF | ? | ||
Reslizumab[34] | Cinqair | mab | humanized | IL-5 | Y | inflammations of the airways, skin and gastrointestinal tract |
Rilotumumab | mab | human | HGF | solid tumors | ||
Rinucumab | mab | human | platelet-derived growth factor receptor beta | neovascular age-related macular degeneration | ||
Risankizumab[7] | mab | humanized | IL23A | Crohn's disease, psoriasis, psoriatic arthritis, and asthma | ||
Rituximab | MabThera, Rituxan | mab | chimeric | CD20 | Y | lymphomas, leukemias, some autoimmune disorders |
Rivabazumab pegol[7] | mab | humanized | Pseudomonas aeruginosa type III secretion system | ? | ||
Robatumumab | mab | human | IGF-1 receptor (CD221) | cancer | ||
Rmab | RabiShield | ? | human | rabies virus G glycoprotein | Y | post-exposure prophylaxis of rabies |
Roledumab[44] | mab | human | RHD | Rh disease | ||
Romilkimab[4] | mab | chimeric/humanized | interleukin 13 | ? | ||
Romosozumab | Evenity | mab | humanized | sclerostin | osteoporosis | |
Rontalizumab | mab | humanized | IFN-α | systemic lupus erythematosus | ||
Rosmantuzumab | mab | humanized | root plate-specific spondin 3 | cancer | ||
Rovalpituzumab tesirine[7] | mab | humanized | DLL3 | small cell lung cancer | ||
Rovelizumab | LeukArrest | mab | humanized | CD11, CD18 | Y | haemorrhagic shock etc. |
Rozanolixizumab[13] | mab | chimeric/humanized | FCGRT | ? | ||
Ruplizumab[10] | Antova | mab | humanized | CD154 (CD40L) | Y | rheumatic diseases |
SA237 | ? | humanized | IL-6R | neuromyelitis optica and neuromyelitis optica spectrum disorders | ||
Sacituzumab govitecan | mab | humanized | TROP-2 | triple-negative breast cancer | ||
Samalizumab | mab | humanized | CD200 | cancer | ||
Samrotamab vedotin[4] | mab | chimeric/humanized | LRRC15 | cancer | ||
Sarilumab | Kevzara | mab | human | IL6 | Y | rheumatoid arthritis, ankylosing spondylitis |
Satralizumab | mab | humanized | IL6 receptor | neuromyelitis optica | ||
Satumomab pendetide | mab | mouse | TAG-72 | cancer (diagnosis) | ||
Secukinumab | Cosentyx | mab | human | IL 17A | Y | uveitis, rheumatoid arthritis psoriasis |
Selicrelumab[17] | mab | human | CD40 | ? | ||
Seribantumab[21] | mab | human | ERBB3 (HER3) | cancer | ||
Setoxaximab[21] | mab | chimeric | E. coli shiga toxin type-2 | ? | ||
Setrusumab[6] | mab | human | SOST | ? | ||
Sevirumab | ? | human | cytomegalovirus | cytomegalovirus infection | ||
Sibrotuzumab | mab | humanized | FAP | cancer | ||
SGN-CD19A | mab | humanized | CD19 | acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma | ||
SHP647 | ? | human | mucosal addressin cell adhesion molecule | Crohn's disease | ||
Sifalimumab | mab | humanized | IFN-α | SLE, dermatomyositis, polymyositis | ||
Siltuximab | Sylvant | mab | chimeric | IL-6 | Y | cancer |
Simtuzumab[33] | mab | humanized | LOXL2 | fibrosis | ||
Siplizumab[12] | mab | humanized | CD2 | psoriasis, graft-versus-host disease (prevention) | ||
Sirtratumab vedotin[6] | mab | human | SLITRK6 | cancer | ||
Sirukumab | mab | human | IL-6 | rheumatoid arthritis | ||
Sofituzumab vedotin | mab | humanized | CA-125 | ovarian cancer | ||
Solanezumab[52] | mab | humanized | beta amyloid | Alzheimer's disease | ||
Solitomab[27] | BiTE | mouse | EpCAM | gastrointestinal, lung, and other cancers | ||
Sonepcizumab[55] | ? | humanized | sphingosine-1-phosphate | choroidal and retinal neovascularization | ||
Sontuzumab[54] | mab | humanized | episialin | |||
Spartalizumab[6] | mab | humanized | PDCD1, CD279 | melanoma | ||
Stamulumab[30][54] | mab | human | myostatin | muscular dystrophy | ||
Sulesomab | LeukoScan | Fab' | mouse | NCA-90 (granulocyte antigen) | osteomyelitis (imaging) | |
Suptavumab | mab | human | RSVFR | medically attended lower respiratory disease | ||
Sutimlimab[4] | mab | chimeric/humanized | C1s | cold agglutinin disease | ||
Suvizumab[46] | mab | humanized | HIV-1 | viral infections | ||
Suvratoxumab[17] | mab | human | Staphylococcus aureus alpha toxin | nosocomial pneumonia | ||
Tabalumab | mab | human | BAFF | B-cell cancers | ||
Tacatuzumab tetraxetan | AFP-Cide | mab | humanized | alpha-fetoprotein | cancer | |
Tadocizumab[54] | Fab | humanized | integrin αIIbβ3 | percutaneous coronary intervention | ||
Talacotuzumab[6] | mab | humanized | CD123 | ? | ||
Talizumab | mab | humanized | IgE | allergic reaction | ||
Tamtuvetmab[23] | Tactress | mab | veterinary | CD52 | ||
Tanezumab[8] | mab | humanized | NGF | pain | ||
Taplitumomab paptox[37] | mab | mouse | CD19 | cancer | ||
Tarextumab | mab | human | Notch receptor | cancer | ||
Tavolimab | mab | chimeric/humanized | CD134 | cancer | ||
Tefibazumab[20] | Aurexis | mab | humanized | clumping factor A | Staphylococcus aureus infection | |
Telimomab aritox | Fab | mouse | ? | |||
Telisotuzumab vedotin | mab | humanized | HGFR | cancer | ||
Tenatumomab[9] | mab | mouse | tenascin C | cancer | ||
Teneliximab[12] | mab | chimeric | CD40 | autoimmune diseases and prevention of organ transplant rejection | ||
Teplizumab[26] | mab | humanized | CD3 | diabetes mellitus type 1 | ||
Tepoditamab[4] | mab | human | dendritic cell-associated lectin 2 | cancer | ||
Teprotumumab | mab | human | IGF-1 receptor (CD221) | thyroid eye disease | ||
Tesidolumab[15] | mab | human | C5 | |||
Tetulomab | mab | humanized | CD37 | cancer[56] | ||
Tezepelumab[7] | mab | human | TSLP | asthma, atopic dermatitis | ||
TGN1412 | ? | humanized | CD28 | chronic lymphocytic leukemia, rheumatoid arthritis | ||
Tibulizumab[6] | mab | humanized | BAFF | autoimmune disorders | ||
Tildrakizumab | Ilumya | mab | humanized | IL23 | Y | immunologically mediated inflammatory disorders |
Tigatuzumab[9] | mab | humanized | TRAIL-R2 | cancer | ||
Timigutuzumab[17] | mab | humanized | HER2 | cancer | ||
Timolumab[23] | mab | human | AOC3 | |||
Tiragotumab[6] | mab | human | TIGIT | cancer | ||
Tislelizumab[6] | mab | humanized | PCDC1, CD279 | non-small cell lung cancer | ||
Tisotumab vedotin[7] | mab | human | coagulation factor III | relapsed or refractory cervical cancer[57] | ||
TNX-650 | ? | humanized | IL-13 | Hodgkin's lymphoma | ||
Tocilizumab[5] | Actemra, RoActemra | mab | humanized | IL-6 receptor | Y | rheumatoid arthritis |
Tomuzotuximab[17] | mab | humanized | EGFR, HER1 | cancer | ||
Toralizumab[12] | mab | humanized | CD154 (CD40L) | rheumatoid arthritis, lupus nephritis etc. | ||
Tosatoxumab[3] | mab | human | Staphylococcus aureus | |||
Tositumomab | Bexxar | ? | mouse | CD20 | Y | follicular lymphoma |
Tovetumab | mab | human | CD140a | cancer | ||
Tralokinumab | mab | human | IL-13 | asthma, atopic dermatitis | ||
Trastuzumab | Herceptin | mab | humanized | HER2/neu | Y | breast cancer |
Trastuzumab emtansine | Kadcyla | mab | humanized | HER2/neu | Y | breast cancer |
TRBS07[58] | Ektomab | 3funct | ? | GD2 ganglioside | melanoma | |
Tregalizumab[16] | mab | humanized | CD4 | |||
Tremelimumab | mab | human | CTLA-4 | non-small cell lung, head & neck, urothelial cancer | ||
Trevogrumab | mab | human | growth differentiation factor 8 | muscle atrophy due to orthopedic disuse and sarcopenia | ||
Tucotuzumab celmoleukin[30][54] | mab | humanized | EpCAM | cancer | ||
Tuvirumab | ? | human | hepatitis B virus | chronic hepatitis B | ||
Ublituximab[16] | mab | chimeric | MS4A1 | multiple sclerosis, chronic lymphocytic leukemia | ||
Ulocuplumab | mab | human | CXCR4 (CD184) | hematologic malignancies | ||
Urelumab | mab | human | 4-1BB (CD137) | cancer etc. | ||
Urtoxazumab[5] | mab | humanized | Escherichia coli | diarrhoea caused by E. coli | ||
Ustekinumab[8] | Stelara | mab | human | IL-12, IL-23 | Y | multiple sclerosis, psoriasis, psoriatic arthritis |
Utomilumab[25] | mab | human | 4-1BB (CD137) | diffuse large B-cell lymphoma | ||
Vadastuximab talirine[7] | mab | chimeric | CD33 | Acute myeloid leukemia | ||
Vanalimab[4] | mab | humanized | CD40 | ? | ||
Vandortuzumab vedotin[15] | mab | humanized | STEAP1 | cancer | ||
Vantictumab | mab | human | Frizzled receptor | cancer | ||
Vanucizumab[19] | mab | humanized | angiopoietin 2 | cancer | ||
Vapaliximab[12] | mab | chimeric | AOC3 (VAP-1) | |||
Varisacumab[17] | mab | human | VEGF-A | angiogenesis | ||
Varlilumab | mab | human | CD27 | solid tumors and hematologic malignancies | ||
Vatelizumab[24] | mab | humanized | ITGA2 (CD49b) | |||
Vedolizumab | Entyvio | mab | humanized | integrin α4β7 | Y | Crohn's disease, ulcerative colitis |
Veltuzumab[9] | mab | humanized | CD20 | non-Hodgkin's lymphoma | ||
Vepalimomab | mab | mouse | AOC3 (VAP-1) | inflammation | ||
Vesencumab[16] | mab | human | NRP1 | solid malignancies | ||
Visilizumab[37] | Nuvion | mab | humanized | CD3 | Crohn's disease, ulcerative colitis | |
Vobarilizumab[23] | scFv | humanized | IL6R | inflammatory autoimmune diseases | ||
Volociximab[18] | mab | chimeric | integrin α5β1 | solid tumors | ||
Vonlerolizumab | mab | humanized | CD134 | cancer | ||
Vopratelimab[4] | mab | humanized | ICOS | ? | ||
Vorsetuzumab mafodotin | mab | humanized | CD70 | cancer | ||
Votumumab | HumaSPECT | mab | human | tumor antigen CTAA16.88 | colorectal tumors | |
Vunakizumab[13] | mab | humanized | interleukin 17 alpha | ? | ||
Xentuzumab[23] | mab | humanized | IGF1, IGF2 | ? | ||
XMAB-5574 | ? | humanized | CD19 | diffuse large B-cell lymphoma | ||
Zalutumumab[18] | HuMax-EGFr | mab | human | EGFR | squamous cell carcinoma of the head and neck | |
Zanolimumab[5] | HuMax-CD4 | mab | human | CD4 | rheumatoid arthritis, psoriasis, T-cell lymphoma | |
Zatuximab[33] | mab | chimeric | HER1 | cancer | ||
Zenocutuzumab[6] | mab | humanized | ERBB3, HER3 | cancer | ||
Ziralimumab[37] | mab | human | CD147 (basigin) | ? | ||
Zolbetuximab[6] | mab | chimeric | CLDN18 | cancer | ||
Zolimomab aritox | mab | mouse | CD5 | systemic lupus erythematosus, graft-versus-host disease |
References
- ↑ "United Therapeutics 10-K report". Retrieved 5 November 2011.
- 1 2 3 4 5 World Health Organization (2006). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 95" (PDF). WHO Drug Information. 20 (2).
- 1 2 3 4 5 6 World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109" (PDF). WHO Drug Information. 27 (2).
- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 118" (PDF). WHO Drug Information. 31 (4).
- 1 2 3 4 5 6 7 World Health Organization (2004). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 90" (PDF). WHO Drug Information. 18 (1).
- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2).
- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).
- 1 2 3 4 5 6 7 World Health Organization (2008). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 99" (PDF). WHO Drug Information. 22 (2).
- 1 2 3 4 5 6 7 8 9 World Health Organization (2007). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 98" (PDF). WHO Drug Information. 21 (4).
- 1 2 3 4 World Health Organization (2000). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 83" (PDF). WHO Drug Information. 14 (2).
- ↑ "Wyeth.com | Complete Project Listing". Wyeth. 2008. Archived from the original on June 12, 2008. Retrieved November 19, 2008.
- 1 2 3 4 5 6 7 8 9 World Health Organization (2002). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 87" (PDF). WHO Drug Information. 16 (2).
- 1 2 3 4 5 6 7 8 9 10 11 12 World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 77" (PDF). WHO Drug Information. 31 (1).
- 1 2 3 World Health Organization (2003). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 88" (PDF). WHO Drug Information. 17 (1).
- 1 2 3 4 5 6 7 8 9 10 World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 112" (PDF). WHO Drug Information. 28 (4).
- 1 2 3 4 5 6 World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104" (PDF). WHO Drug Information. 24 (4).
- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116" (PDF). WHO Drug Information. 30 (4).
- 1 2 3 4 5 6 7 8 World Health Organization (2008). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 93" (PDF). WHO Drug Information. 19 (2).
- 1 2 3 4 5 6 7 8 9 10 World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
- 1 2 3 4 World Health Organization (2004). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 92" (PDF). WHO Drug Information. 18 (4).
- 1 2 3 4 5 6 7 8 9 World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 108" (PDF). WHO Drug Information. 26 (4).
- 1 2 World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).
- 1 2 3 4 5 World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2).
- 1 2 3 4 5 World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).
- 1 2 3 4 World Health Organization (2007). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 97" (PDF). WHO Drug Information. 21 (2).
- 1 2 3 4 5 World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106" (PDF). WHO Drug Information. 25 (4).
- ↑ "BMS Shells Out $85M Up Front for Alder's Mid-Stage Rheumatoid Arthritis Antibody". Genetic Engineering & Biotechnology News. 10 November 2009.
- 1 2 World Health Organization (2009). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 101" (PDF). WHO Drug Information. 23 (2).
- 1 2 3 4 5 6 7 World Health Organization (2005). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 94" (PDF). WHO Drug Information. 19 (4).
- ↑ World Health Organization (1991). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 66" (PDF). WHO Drug Information. 5 (4).
- 1 2 3 World Health Organization (2018). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 119" (PDF). WHO Drug Information. 32 (2).
- 1 2 3 4 5 6 7 8 9 10 11 12 World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
- 1 2 3 4 World Health Organization (2001). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 85" (PDF). WHO Drug Information. 15 (2).
- ↑ World Health Organization (1997). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 77" (PDF). WHO Drug Information. 11 (2).
- ↑ World Health Organization (2004). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 51" (PDF). WHO Drug Information. 18 (1).
- 1 2 3 4 5 6 7 World Health Organization (2000). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 84" (PDF). WHO Drug Information. 14 (4).
- 1 2 3 4 World Health Organization (2004). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 91" (PDF). WHO Drug Information. 18 (2).
- 1 2 3 World Health Organization (2002). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 86" (PDF). WHO Drug Information. 16 (12).
- ↑ Buhmann, R; Simoes, B; Stanglmaier, M; Yang, T; Faltin, M; Bund, D; Lindhofer, H; Kolb, HJ; et al. (2008). "Immunotherapy of recurrent B–cell malignancies after allo SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion". Bone Marrow Transplantation. 43 (5): 383–397. doi:10.1038/bmt.2008.323. PMID 18850012.
- ↑ Boehrer, S; Schroeder, Petra; Mueller, Tina; Atz, Judith; Chow, Kai Uwe; et al. (2011). "Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanisms". Anti-Cancer Drugs. 12 (10): 3085–3091. doi:10.1097/CAD.0b013e328344887f. PMID 21637160.
- ↑ Clinical trial number NCT00883896 for "Study to Evaluate the Safety and Efficacy of ILV-094 in Subjects With Rheumatoid Arthritis" at ClinicalTrials.gov
- ↑ Clinical trial number NCT00563524 for "Study Evaluating the Safety and Tolerability of ILV-094 in Subjects With Psoriasis" at ClinicalTrials.gov
- 1 2 3 4 World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103" (PDF). WHO Drug Information.
- ↑ http://www.prnewswire.com/news-releases/prometheus-obtains-exclusive-us-commercialization-rights-for-rencarex-121075044.html
- 1 2 World Health Organization (2009). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 102" (PDF). WHO Drug Information. 23 (4).
- ↑ NCI Drug Dictionary: Glemtumumab vedotin
- ↑ Clinical trial number NCT00537381 for "A Study of the Safety and Effectiveness of CNTO 95 in Patients With Metastatic Hormone Refractory Prostate Cancer" at ClinicalTrials.gov
- ↑ Clinical trial number NCT00246012 for "A Study of the Safety and Efficacy CNTO 95 in Subjects With Advanced Melanoma" at ClinicalTrials.gov
- 1 2 Guthrie, Arlo (27 June 2017). "Zoetis launches breakthrough treatment for canine atopic dermatitis". VetNurse News. Retrieved 2018-07-06.
- ↑ World Health Organization (2006). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 96" (PDF). WHO Drug Information. 20 (4).
- 1 2 3 4 5 World Health Organization (2008). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 100 (prepublication copy)" (PDF). WHO Drug Information.
- ↑ http://www.nejm.org/doi/full/10.1056/NEJMoa1606490
- 1 2 3 4 5 World Health Organization (2006). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 56" (PDF). WHO Drug Information. 20 (3).
- ↑ Xie, B.; Shen, J.; Dong, A.; Rashid, A.; Stoller, G.; Campochiaro, P. A. (2009). "Blockade of Sphingosine-1-phosphate Reduces Macrophage Influx and Retinal and Choroidal Neovascularization". Journal of Cellular Physiology. 218 (1): 192–198. doi:10.1002/jcp.21588. PMC 2905312. PMID 18781584.
- ↑ Jostein Dahle; Ada H. V. Repetto-Llamazares; Camilla S. Mollatt; Katrine B. Melhus; Oyvind S. Bruland; Arne Kolstad; Roy H. Larsen (January 2013). "Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma". Anticancer research. 33 (1): 85–95. PMID 23267131.
- ↑ Wright, Rob (13 February 2018). "Seattle Genetics Legacy Of Partnering". Life Science Leader. Beyond The Printed Page. Retrieved 22 February 2018.
- ↑ Ruf, P; Jäger, M; Ellwart, J; Wosch, S; Kusterer, E; Lindhofer, H; et al. (2004). "Two new trifunctional antibodies for the therapy of human malignant melanoma". International Journal of Cancer. 108 (5): 725–732. doi:10.1002/ijc.11630. PMID 14696099.
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.